Tissue Regenix Group
plc
('Tissue Regenix' or
'the Group')
Grant of share options
Tissue Regenix (AIM: TRX), the regenerative
medical devices company, announces that Daniel
Lee, Chief Executive Officer, and David Cocke, Chief Financial
Officer, have each been granted on 17 July 2024 an award of
restricted share units ("RSUs") and Kirsten Lund EMEA Business
Director a Conditional Share Award (CSA) with respect to ordinary
shares in the capital of the Company ("Ordinary Shares")
under the existing annual Tissue Regenix Share Incentive Plan
following the publication of the 2024 trading update.
Daniel Lee has been awarded
175,743 RSUs and David Cocke has been awarded 136,353 RSUs
and Kirsten Lund has been awarded 49,798 Conditional Awards,
where each RSU/CSA that vests shall represent the
right to receive payment of one Ordinary Share. The exercise price
of the RSUs is 0.1p per Ordinary Share. The RSUs/CSA are
subject to continued service over a period of
three years and satisfaction of customary
performance conditions relating to growth in total shareholder
return, annual revenue targets, annual profitability targets and
personal performance targets.
Following the grant of these options, Daniel
Lee and David Cocke hold options over a total of 649,425 and
503,865 RSUs respectively representing 0.9% and 0.7% of the
current issued share capital respectively. Kirsten
Lund holds options over a total of 185,796 CSA
representing 0.3% of the current issued share
capital.
For more
information:
|
Tissue Regenix
Group plc
|
www.tissueregenix.com
|
|
Daniel Lee, Chief Executive
Officer
David Cocke, Chief Financial Officer
|
via Walbrook
PR
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
|
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
|
|
|
Nigel Birks/Harriet Ward - ECM
|
|
|
|
|
|
Walbrook PR (Financial PR and IR)
|
Tel: +44
(0)20 7933 8780
|
|
Charlotte Edgar / Alice Woodings
|
TissueRegenix@walbrookpr.com
|
|
|
|
The
information contained within this announcement is deemed by the
Company to constitute inside information as stipulated under the
Market Abuse Regulation 'MAR' EU no.596/2014. Upon the publication
of this announcement via the Regulatory Information Service 'RIS',
this inside information is now considered to be in the public
domain.
About Tissue Regenix
(www.tissueregenix.com)
Tissue Regenix is a leading medical device
company in regenerative medicine. The Company's patented
decellularisation technology (dCELL®) removes DNA and other
cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that
can be used to repair diseased or damaged body structures. Current
applications address many crucial clinical needs in sports
medicine, foot and ankle injuries and wound care.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated ("PCA") with them.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Daniel Lee
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
CEO
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Tissue Regenix Group plc
|
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Restricted share units ("RSUs") with
respect to ordinary shares in the capital of the Company of
0.1p
|
|
b)
|
Identification code
|
GB00B5SGVL29
|
|
c)
|
Nature of the
transaction
|
Issue of options
|
|
d)
|
Price(s) and volume(s)
|
Volume(s):
175,743 RSUs
Price: 0.1 pence per RSU
|
|
d)
|
Aggregated
information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the
transactions
|
17 July 2024
|
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
David Cocke
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
CFO
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Tissue Regenix Group plc
|
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Restricted share units ("RSUs") with
respect to ordinary shares in the capital of the Company of
0.1p
|
|
b)
|
Identification code
|
GB00B5SGVL29
|
|
c)
|
Nature of the
transaction
|
Issue of options
|
|
d)
|
Price(s) and volume(s)
|
Volume(s):
136,353 RSUs
Price: 0.1 pence per RSU
|
|
d)
|
Aggregated
information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the
transactions
|
17 July 2024
|
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Kirsten Lund
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
EMEA Business Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Tissue Regenix Group plc
|
|
b)
|
LEI
|
213800PNOD5UHQUFJI36
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Conditional Share awards with
respect to ordinary shares in the capital of the Company of
0.1p
|
|
b)
|
Identification code
|
GB00B5SGVL29
|
|
c)
|
Nature of the
transaction
|
Issue of options
|
|
d)
|
Price(s) and volume(s)
|
Volume(s):
49,798 CSAs
Price: 0.1 pence per SCA
|
|
d)
|
Aggregated
information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the
transactions
|
17 July 2024
|
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
